New prospects and strategies for drug target discovery in neurodegenerative disorders

Brian S. Hilbush, John Morrison, Warren G. Young, J. Gregor Sutcliffe, Floyd E. Bloom

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

The future of neurodegenerative therapeutics development depends upon effective disease modification strategies centered on carefully investigated targets. Pharmaceutical research endeavors that probe for a much deeper understanding of disease pathogenesis, and explain how adaptive or compensatory mechanisms might be engaged to delay disease onset or progression, will produce the needed breakthroughs. Below, we discuss the prospects for new targets emerging out of the study of brain disease genes and their associated pathogenic pathways. We describe a general experimental paradigm that we are employing across several mouse models of neurodegenerative disease to elucidate molecular determinants of selective neuronal vulnerability. We outline key elements of our target discovery program and provide examples of how we integrate genomic technologies, neuroanatomical methods, and mouse genetics in the search for neurodegenerative disease targets.

Original languageEnglish (US)
Pages (from-to)627-637
Number of pages11
JournalNeuroRx
Volume2
Issue number4
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Drug Discovery
Neurodegenerative Diseases
Brain Diseases
Technology
Genes
Therapeutics

Keywords

  • Alzheimer's
  • Genes
  • Genomics
  • Neurodegeneration
  • QTL
  • Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

New prospects and strategies for drug target discovery in neurodegenerative disorders. / Hilbush, Brian S.; Morrison, John; Young, Warren G.; Sutcliffe, J. Gregor; Bloom, Floyd E.

In: NeuroRx, Vol. 2, No. 4, 01.01.2005, p. 627-637.

Research output: Contribution to journalReview article

Hilbush, Brian S. ; Morrison, John ; Young, Warren G. ; Sutcliffe, J. Gregor ; Bloom, Floyd E. / New prospects and strategies for drug target discovery in neurodegenerative disorders. In: NeuroRx. 2005 ; Vol. 2, No. 4. pp. 627-637.
@article{c56159eef8c14fcc99e4ba91f29bac03,
title = "New prospects and strategies for drug target discovery in neurodegenerative disorders",
abstract = "The future of neurodegenerative therapeutics development depends upon effective disease modification strategies centered on carefully investigated targets. Pharmaceutical research endeavors that probe for a much deeper understanding of disease pathogenesis, and explain how adaptive or compensatory mechanisms might be engaged to delay disease onset or progression, will produce the needed breakthroughs. Below, we discuss the prospects for new targets emerging out of the study of brain disease genes and their associated pathogenic pathways. We describe a general experimental paradigm that we are employing across several mouse models of neurodegenerative disease to elucidate molecular determinants of selective neuronal vulnerability. We outline key elements of our target discovery program and provide examples of how we integrate genomic technologies, neuroanatomical methods, and mouse genetics in the search for neurodegenerative disease targets.",
keywords = "Alzheimer's, Genes, Genomics, Neurodegeneration, QTL, Therapeutics",
author = "Hilbush, {Brian S.} and John Morrison and Young, {Warren G.} and Sutcliffe, {J. Gregor} and Bloom, {Floyd E.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1602/neurorx.2.4.627",
language = "English (US)",
volume = "2",
pages = "627--637",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - New prospects and strategies for drug target discovery in neurodegenerative disorders

AU - Hilbush, Brian S.

AU - Morrison, John

AU - Young, Warren G.

AU - Sutcliffe, J. Gregor

AU - Bloom, Floyd E.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The future of neurodegenerative therapeutics development depends upon effective disease modification strategies centered on carefully investigated targets. Pharmaceutical research endeavors that probe for a much deeper understanding of disease pathogenesis, and explain how adaptive or compensatory mechanisms might be engaged to delay disease onset or progression, will produce the needed breakthroughs. Below, we discuss the prospects for new targets emerging out of the study of brain disease genes and their associated pathogenic pathways. We describe a general experimental paradigm that we are employing across several mouse models of neurodegenerative disease to elucidate molecular determinants of selective neuronal vulnerability. We outline key elements of our target discovery program and provide examples of how we integrate genomic technologies, neuroanatomical methods, and mouse genetics in the search for neurodegenerative disease targets.

AB - The future of neurodegenerative therapeutics development depends upon effective disease modification strategies centered on carefully investigated targets. Pharmaceutical research endeavors that probe for a much deeper understanding of disease pathogenesis, and explain how adaptive or compensatory mechanisms might be engaged to delay disease onset or progression, will produce the needed breakthroughs. Below, we discuss the prospects for new targets emerging out of the study of brain disease genes and their associated pathogenic pathways. We describe a general experimental paradigm that we are employing across several mouse models of neurodegenerative disease to elucidate molecular determinants of selective neuronal vulnerability. We outline key elements of our target discovery program and provide examples of how we integrate genomic technologies, neuroanatomical methods, and mouse genetics in the search for neurodegenerative disease targets.

KW - Alzheimer's

KW - Genes

KW - Genomics

KW - Neurodegeneration

KW - QTL

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=25844469582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25844469582&partnerID=8YFLogxK

U2 - 10.1602/neurorx.2.4.627

DO - 10.1602/neurorx.2.4.627

M3 - Review article

VL - 2

SP - 627

EP - 637

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 4

ER -